Mutual of America Capital Management LLC Makes New $701,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mutual of America Capital Management LLC acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 35,056 shares of the biotechnology company’s stock, valued at approximately $701,000.

Several other large investors have also recently added to or reduced their stakes in ADMA. Assenagon Asset Management S.A. raised its holdings in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares in the last quarter. Seven Eight Capital LP acquired a new stake in ADMA Biologics during the second quarter valued at $1,992,000. Principal Financial Group Inc. lifted its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in ADMA Biologics during the third quarter worth approximately $2,253,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $1,157,000. 75.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Raymond James lifted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th.

Insider Activity

In related news, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the transaction, the director now directly owns 467,305 shares in the company, valued at approximately $8,070,357.35. The trade was a 22.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 185,011 shares of company stock worth $3,255,204 over the last ninety days. Insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Up 1.6 %

Shares of NASDAQ:ADMA opened at $21.82 on Wednesday. The company has a 50 day moving average price of $18.92 and a two-hundred day moving average price of $15.05. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market capitalization of $5.16 billion, a PE ratio of 77.04 and a beta of 0.64. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the firm earned $0.01 EPS. Analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.